Breast Cancer

Endocrine Therapy

ER/PR-POSITIVE HER2 NEGATIVE

HER2 POSITIVE

"TRIPLE NEGATIVE" EP/PR –NEGATIVE HER2-NEGATIVE

Pre-Op Therapy

CDK 4/6i + PARPi

IRB# 6256-SPY2 Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2

No Trial Currently Available

Surgical Therapy

IRB# 17461 S1418
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy

Adjuvant Therapy

1st line MBC Therapy

No Trials Currently Available

2nd line MBC Therapy

IRB#19708
S1501: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER2+ BC, Phase III

3rd line MBC Therapy

IRB# 19200 DS-8201a Compared to Treatment of Physician’s Choice for HER2-low Unresectable /Metastatic Breast Cancer

No Trial Currently Available

“Heavily Pre-treated” Therapy

IRB#19358
Elacestrant Monotherapy vs. SOC for Advanced BC following CDK4/6 Inhibitor Therapy

IRB# 17887
SGN-LIV1A Part E

IRB#19930
T-DM1 and Palbociclib in Metastatic HER2+ BC

IRB# 18540
Phase 2 Olaparib and Durvalumab in Patients with Metastatic Triple Negative Breast Cancer

IRB 15588 SMMART

No Trials Currently Available

http://www.ohsu.edu/research/rda/so/knight.php

06/28/2019